bortezomib + tirelizumab

Bortezomib + tirelizumab is a combination drug consisting of bortezomib, a proteasome inhibitor used primarily in the treatment of multiple myeloma, and tirelizumab, an immune checkpoint inhibitor targeting PD-1. Bortezomib works by inhibiting the 26S proteasome, leading to disruption of protein degradation and inducing apoptosis in cancer cells. Tirelizumab is a monoclonal antibody that blocks the programmed death-1 (PD-1) receptor on T cells, enhancing immune response against tumor cells. This combination aims to leverage both direct anti-myeloma cytotoxicity and immunotherapy to improve treatment outcomes in cancers such as multiple myeloma. Bortezomib was approved for multiple myeloma treatment since 2003 with various combination regimens showing efficacy; ongoing trials are exploring combinations with monoclonal antibodies like PD-1 inhibitors. Tirelizumab is an anti-PD-1 antibody under clinical development for various cancers but specific approval status or detailed data on this exact combination are limited.